Glaxo has agreed to the FDA 's request to conduct a new trial of Avandia , and the agency will ask that the medicine be compared directly with Actos and perhaps other drugs , Janet Woodcock , acting director of the agency 's Center for Drug Evaluation and Research , said in a conference call with reporters .